Clinical trials
Terminated Leukemia, Promyelocytic, Acute trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
12 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2007 | 3 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2014 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 12 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fred Hutchinson Cancer Center | 2 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 |
| Aegera Therapeutics | 1 |
| Alliance for Clinical Trials in Oncology | 1 |
| Emory University | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| Northwestern University | 1 |
| Shanghai Jiao Tong University School of Medicine | 1 |
| Skyline Diagnostics BV | 1 |
| Stanford University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Promyelocytic, Acute | 12 |
| Leukemia, Myeloid, Acute | 7 |
| Leukemia | 6 |
| Congenital Abnormalities | 4 |
| Leukemia, Erythroblastic, Acute | 4 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 |
| Leukemia, Megakaryoblastic, Acute | 3 |
| Leukemia, Monocytic, Acute | 3 |
| Leukemia, Myelomonocytic, Acute | 3 |
| Myelodysplastic Syndromes | 3 |
Trials
Showing 51 to 12 of 12. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.